Breaking News

Idifarma Gains High Potency Authorization

January 14, 2013

Adds to manufacturing capabilities

Idifarma, a Spanish contract development organization, has obtained authorization from the Spanish Agency of Medicines and Medical Devices to manufacture commercial batches of both conventional and high potency tablets.
With this authorization, the company can manufacture commercial batches of tablets with high level of specialization due to high containment requirements (cytotoxics, cytostatics, hormonals), or the need to manufacture small-sized batches.
Idifarma was previously authorized to manufacture batches for clinical trials, as well as for quality control and release of medicines for both commercial and investigational products.
General manager Luis Oquiñena said, “IDIFARMA will remain essentially a contract research laboratory specialized in the comprehensive development of medicines for our clients, but without any doubt, this new manufacturing authorization will allow us to offer an even more complete service beyond the elaboration of the registration dossier, and turns us into a long-term partner for our clients.”

Related Contract Manufacturing:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research